OBJECTIVE: To develop a simple, valid, repeatable, and readily understandable patient-oriented assessment measure for monitoring disease activity in children and adults with atopic eczema. DESIGN: Qualitative semistructured patient interviews identified a list of symptoms of atopic eczema. These symptoms were quantitatively analyzed in a larger patient population to identify which symptoms were important to patients and amenable to monitoring as part of a scoring system. SETTING: The outpatient Department of Dermatology at the Queen's Medical Centre, University Hospital, Nottingham, England, and 5 local general practices. PATIENTS: Four hundred thirty-five patients with atopic eczema. RESULTS: Seven symptoms were incorporated into the final patient-oriented eczema measure using a simple 5-point scale of frequency of occurrence during the previous week, with a maximum total score of 28. Validity testing against the Dermatology Life Quality Index, Children's Dermatology Life Quality Index, and patients' global severity assessments showed good correlation (r = 0.78, r = 0.73, and r = 0.81, respectively; P<.001). Internal consistency was high (Cronbach alpha = 0.88), and test-retest reliability was good, with 95% of scores falling within 2.6 points on repeat testing (mean score difference, 0.04; SD, 1.32). Individual variables in the measure demonstrated sensitivity to change during a 4-week in-clinic period and an 18-week randomized controlled clinical trial. CONCLUSION: The patient-oriented eczema measure is a practical self-assessed measurement tool for monitoring aspects of atopic eczema that are important to patients in routine clinical practice or in the clinical trial setting.
RCT Entities:
OBJECTIVE: To develop a simple, valid, repeatable, and readily understandable patient-oriented assessment measure for monitoring disease activity in children and adults with atopic eczema. DESIGN: Qualitative semistructured patient interviews identified a list of symptoms of atopic eczema. These symptoms were quantitatively analyzed in a larger patient population to identify which symptoms were important to patients and amenable to monitoring as part of a scoring system. SETTING: The outpatient Department of Dermatology at the Queen's Medical Centre, University Hospital, Nottingham, England, and 5 local general practices. PATIENTS: Four hundred thirty-five patients with atopic eczema. RESULTS: Seven symptoms were incorporated into the final patient-oriented eczema measure using a simple 5-point scale of frequency of occurrence during the previous week, with a maximum total score of 28. Validity testing against the Dermatology Life Quality Index, Children's Dermatology Life Quality Index, and patients' global severity assessments showed good correlation (r = 0.78, r = 0.73, and r = 0.81, respectively; P<.001). Internal consistency was high (Cronbach alpha = 0.88), and test-retest reliability was good, with 95% of scores falling within 2.6 points on repeat testing (mean score difference, 0.04; SD, 1.32). Individual variables in the measure demonstrated sensitivity to change during a 4-week in-clinic period and an 18-week randomized controlled clinical trial. CONCLUSION: The patient-oriented eczema measure is a practical self-assessed measurement tool for monitoring aspects of atopic eczema that are important to patients in routine clinical practice or in the clinical trial setting.
Authors: E Haufe; S Abraham; A Heratizadeh; I Harder; A Zink; E Weisshaar; A Kleinheinz; R von Kiedrowski; M Worm; M Bell; A Wollenberg; K Neubert; P Staubach-Renz; M Hilgers; T Bieber; I Fell; B Homey; I Effendy; M Mempel; K Schäkel; S Beissert; S Weidinger; T Werfel; J Schmitt Journal: Hautarzt Date: 2018-10 Impact factor: 0.751
Authors: Nick A Francis; Matthew J Ridd; Emma Thomas-Jones; Christopher C Butler; Kerenza Hood; Victoria Shepherd; Charis A Marwick; Chao Huang; Mirella Longo; Mandy Wootton; Frank Sullivan Journal: Ann Fam Med Date: 2017-03 Impact factor: 5.166
Authors: Susannah Mc George; Sanja Karanovic; David A Harrison; Anjna Rani; Andrew J Birnie; Fiona J Bath-Hextall; Jane C Ravenscroft; Hywel C Williams Journal: Cochrane Database Syst Rev Date: 2019-10-29
Authors: P P Vakharia; R Chopra; R Sacotte; N Patel; S Immaneni; T White; R Kantor; D Y Hsu; E L Simpson; J I Silverberg Journal: Br J Dermatol Date: 2018-03-06 Impact factor: 9.302
Authors: Marjolein G Willemsen; Rosalinda W C van Valburg; Pauline C Dirven-Meijer; Arnold P Oranje; Johannes C van der Wouden; Heleen Moed Journal: Dermatol Res Pract Date: 2009-11-18
Authors: Lawrence F Eichenfield; Wynnis L Tom; Sarah L Chamlin; Steven R Feldman; Jon M Hanifin; Eric L Simpson; Timothy G Berger; James N Bergman; David E Cohen; Kevin D Cooper; Kelly M Cordoro; Dawn M Davis; Alfons Krol; David J Margolis; Amy S Paller; Kathryn Schwarzenberger; Robert A Silverman; Hywel C Williams; Craig A Elmets; Julie Block; Christopher G Harrod; Wendy Smith Begolka; Robert Sidbury Journal: J Am Acad Dermatol Date: 2013-11-27 Impact factor: 11.527
Authors: Marc K Walton; John H Powers; Jeremy Hobart; Donald Patrick; Patrick Marquis; Spiros Vamvakas; Maria Isaac; Elizabeth Molsen; Stefan Cano; Laurie B Burke Journal: Value Health Date: 2015-08-24 Impact factor: 5.725
Authors: Carolyn Lou; Nandita Mitra; Bradley Wubbenhorst; Kurt D'Andrea; Ole Hoffstad; Brian S Kim; Albert Yan; Andrea L Zaenglein; Zelma Chiesa Fuxench; Katherine L Nathanson; David J Margolis Journal: Ann Allergy Asthma Immunol Date: 2019-09-04 Impact factor: 6.347